StockNews.com began coverage on shares of Charles River Laboratories International (NYSE:CRL – Get Rating) in a research report issued on Thursday. The brokerage set a “hold” rating on the medical research company’s stock. Several other equities research analysts also recently commented on CRL. Wells Fargo & Company cut their target price on shares of Charles […]
Artisan Partners Limited Partnership decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 18.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,258 shares of the medical research company’s stock after selling 3,534 shares during […]
New Hampshire Trust acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 518 shares of the medical research company’s stock, valued at approximately $113,000. A number of other hedge […]
Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) EVP Joseph W. Laplume sold 345 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $190.39, for a total transaction of $65,684.55. Following the transaction, the executive vice president now owns 24,026 shares in […]
FDx Advisors Inc. reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 16.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,531 shares of the medical research company’s stock after selling 1,934 shares during the […]